Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Accenture
Boehringer Ingelheim
QuintilesIMS
Citi
Cipla
Argus Health
Queensland Health
Daiichi Sankyo
Healthtrust

Generated: January 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,296,694

« Back to Dashboard

Summary for Patent: 9,296,694
Title:Azacyclic compounds
Abstract: Compounds and methods are provided for the treatment of disease conditions in which modification of serotonergic receptor activity has a beneficial effect. In the method, an effective amount of a compound is adminstered to a patient in need of such treatment.
Inventor(s): Andersson; Carl-Magnus A. (Glostrup, DK), Croston; Glenn (San Diego, CA), Hansen; Eva Louise (Glostrup, DK), Uldam; Allan Kjaersgaard (Glostrup, DK)
Assignee: ACADIA PHARMACEUTICALS INC. (San Diego, CA)
Application Number:14/628,156
Patent Claim Types:
see list of patent claims
Compound;

Drugs Protected by US Patent 9,296,694

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Acadia Pharms Inc NUPLAZID pimavanserin tartrate TABLET;ORAL 207318-001 Apr 29, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,296,694

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
2,017,165,273 ➤ Subscribe
6,756,393 Azacyclic compounds ➤ Subscribe
9,765,053 Methods of treatment using selective 5-HT2A inverse agonists ➤ Subscribe
6,815,458 Azacyclic compounds ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,296,694

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 1263729 ➤ Subscribe
European Patent Office 1787984 ➤ Subscribe
Spain 2278729 ➤ Subscribe
Hong Kong 1051684 ➤ Subscribe
Israel 151164 ➤ Subscribe
Russian Federation 2002126554 ➤ Subscribe
Russian Federation 2007139896 ➤ Subscribe
Russian Federation 2398765 ➤ Subscribe
Portugal 1263729 ➤ Subscribe
New Zealand 520240 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
Cantor Fitzgerald
Moodys
Julphar
Chubb
UBS
AstraZeneca
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot